Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients

Durślewicz, Justyna; Klimaszewska‐Wiśniewska, Anna; Jóźwicki, Jakub; Antosik, Paulina; Kozerawski, Kamil; Grzanka, Dariusz; Braun, Marcin

doi:10.1007/s00432-022-04097-9

Cited by 9 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11] Likewise, in our previous report, we revealed that low MATR3 protein expression was an independent poor prognostic factor in non-small cell lung cancer. [12] In the current study, low MATR3 expression in our cohort and TCGA cohort was a negative prognostic factor in both univariate and multivariate analysis. The opposite relationship was presented by Yang et al with regard to neuroblastoma.…”

Section: Discussionsupporting

confidence: 45%

Low expression of MATR3 is associated with poor survival in clear cell renal cell carcinoma

Durślewicz

Klimaszewska‐Wiśniewska

Antosik

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Matrin 3 (MATR3) is one of the most abundant inner nuclear matrix proteins involved in multiple nuclear processes. To date the biological role and prognostic relevance of MATR3 in human cancers remain largely underexplored. Therefore, the aim of the present study was to examine the expression levels and prognostic significance of MATR3 in clear cell renal cell carcinoma (ccRCC) patients. We assessed MATR3 immunohistochemical staining and RNA-seq data from publicly available data sets, and the results were analyzed with reference to clinicopathological characteristics and overall survival of patients. Furthermore, protein-protein interaction (PPI) network for MATR3 and its neighbors was constructed, functionally annotated, and screened for survival-related genes. We observed that MATR3 protein and mRNA levels were lower in tumor tissues compared to control tissues. Lower MATR3 protein and mRNA expression levels were found to be a significant independent adverse prognostic factor for patient overall survival (OS). Moreover, out of the candidate genes, MRPL23 gene was identified as being the most predictive of OS and combined MRPL23/MATR3 expression status predicted patient survival better than looking at each marker individually. In conclusion, the present investigation warrants further research into the biological and prognostic value of MATR3 and MRPL23 in ccRCC patients.

show abstract

Section: Discussionsupporting

confidence: 45%

Low expression of MATR3 is associated with poor survival in clear cell renal cell carcinoma

Durślewicz

Klimaszewska‐Wiśniewska

Antosik

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, high MATR3 levels are associated with better prognosis in breast cancer patients. Similarly, high MATR3 protein expression was also associated with higher overall survival in patients with non-small cell lung cancer [ 30 ] or clear-cell renal cell carcinoma [ 31 ]. Taken together, these studies demonstrate that MATR3 dysregulation is associated with cancer, but it may play a different role depending on the cancer type.…”

Section: Matr3 In the Context Of Diseasementioning

confidence: 99%

“…Most notably, missense mutations in MATR3 have been linked to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease caused by the loss of motor neurons [ 24 ], as well as in neurodevelopmental diseases [ 16 , 25 ]. Furthermore, recent studies have revealed that MATR3 may play a critical role in other diseases, including cancer [ 26 , 27 , 28 , 29 , 30 , 31 ].…”

Section: Introductionmentioning

confidence: 99%

MATR3’s Role beyond the Nuclear Matrix: From Gene Regulation to Its Implications in Amyotrophic Lateral Sclerosis and Other Diseases

Santos,

Park

2024

Cells

View full text Add to dashboard Cite

Matrin-3 (MATR3) was initially discovered as a component of the nuclear matrix about thirty years ago. Since then, accumulating studies have provided evidence that MATR3 not only plays a structural role in the nucleus, but that it is also an active protein involved in regulating gene expression at multiple levels, including chromatin organization, DNA transcription, RNA metabolism, and protein translation in the nucleus and cytoplasm. Furthermore, MATR3 may play a critical role in various cellular processes, including DNA damage response, cell proliferation, differentiation, and survival. In addition to the revelation of its biological role, recent studies have reported MATR3’s involvement in the context of various diseases, including neurodegenerative and neurodevelopmental diseases, as well as cancer. Moreover, sequencing studies of patients revealed a handful of disease-associated mutations in MATR3 linked to amyotrophic lateral sclerosis (ALS), which further elevated the gene’s importance as a topic of study. In this review, we synthesize the current knowledge regarding the diverse functions of MATR3 in DNA- and RNA-related processes, as well as its involvement in various diseases, with a particular emphasis on ALS.

show abstract

“…by binding to m6A-containing MYC mRNAs which may inflict with MYC protein synthesis. Among several tumors, overexpression of MATR3 has been associated with hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) stageI/II development and has tumor-suppressive activity in basal-like breast cancer [38][39][40]. Quite important, Matrin 3 has been described as essential for the stabilization of chromatin architecture and the regulation of differentiation processes [41].…”

Section: Novel Translocation Partner Genesmentioning

confidence: 99%

The KMT2A recombinome of acute leukemias in 2023

et al. 2023

View full text Add to dashboard Cite

Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5’-KMT2A, two patients had a 5’-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the KMT2A recombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival.

show abstract

Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients

Cited by 9 publications

References 37 publications

Low expression of MATR3 is associated with poor survival in clear cell renal cell carcinoma

Low expression of MATR3 is associated with poor survival in clear cell renal cell carcinoma

MATR3’s Role beyond the Nuclear Matrix: From Gene Regulation to Its Implications in Amyotrophic Lateral Sclerosis and Other Diseases

The KMT2A recombinome of acute leukemias in 2023

Contact Info

Product

Resources

About